VRCA
Income statement / Annual
Last year (2023), Verrica Pharmaceuticals Inc.'s total revenue was $5.12 M,
a decrease of 43.27% from the previous year.
In 2023, Verrica Pharmaceuticals Inc.'s net income was -$67.00 M.
See Verrica Pharmaceuticals Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$5.12 M
|
$9.03 M
|
$12.00 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$746,000.00 |
$725,000.00 |
$472,000.00 |
$229,000.00 |
$257,199.00 |
$20,294.00 |
$0.00 |
$0.00 |
| Gross Profit |
$4.38 M |
$8.31 M |
$11.53 M |
-$229,000.00 |
-$257,199.00 |
-$20,294.00 |
$0.00 |
$0.00 |
| Gross Profit Ratio |
0.85 |
0.92 |
0.96 |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$20.30 M
|
$12.20 M
|
$15.93 M
|
$15.67 M
|
$15.44 M
|
$12.83 M
|
$3.73 M
|
$1.71 M
|
| General & Administrative
Expenses |
$0.00
|
$17.41 M
|
$26.98 M
|
$24.51 M
|
$14.64 M
|
$9.05 M
|
$727,000.00
|
$204,000.00
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$47.31 M
|
$17.41 M
|
$26.98 M
|
$24.51 M
|
$14.64 M
|
$9.05 M
|
$727,000.00
|
$204,000.00
|
| Other Expenses |
$2.54 M |
-$58,000.00 |
$0.00 |
-$1,000.00 |
$1.87 M |
-$1,000.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$70.59 M |
$29.60 M |
$42.91 M |
$40.18 M |
$30.08 M |
$21.88 M |
$4.46 M |
$1.91 M |
| Cost And Expenses |
$70.88 M |
$30.33 M |
$42.91 M |
$40.18 M |
$30.08 M |
$21.88 M |
$4.46 M |
$1.91 M |
| Interest Income |
$2.74 M |
$476,000.00 |
$123,000.00 |
$521,000.00 |
$1.88 M |
$1.23 M |
$0.00 |
$0.00 |
| Interest Expense |
$3.96 M |
$2.17 M |
$4.30 M |
$3.03 M |
$0.00 |
$0.00 |
$2,000.00 |
$0.00 |
| Depreciation &
Amortization |
$836,000.00
|
$718,000.00
|
$472,000.00
|
$229,000.00
|
$257,199.00
|
$20,294.00
|
$4.46 M
|
$1.91 M
|
| EBITDA |
-$62.20 M
|
-$21.60 M
|
-$30.31 M
|
-$39.43 M
|
-$30.08 M
|
-$20.63 M
|
-$4.46 M
|
-$1.91 M
|
| EBITDA Ratio |
-12.14 |
-2.31 |
-2.57 |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
-12.83
|
-2.36
|
-2.58
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
-$1.24 M
|
-$3.19 M
|
-$4.17 M
|
-$2.51 M
|
$1.87 M
|
$1.23 M
|
-$2,000.00
|
$0.00
|
| Income Before Tax |
-$67.00 M |
-$24.49 M |
-$35.08 M |
-$42.69 M |
-$28.21 M |
-$20.65 M |
-$4.46 M |
-$1.91 M |
| Income Before Tax Ratio
|
-13.07
|
-2.71
|
-2.92
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00 |
$3.19 M |
$3.82 M |
$2.80 M |
-$257,000.00 |
$1.23 M |
-$4.46 M |
-$1.91 M |
| Net Income |
-$67.00 M |
-$27.68 M |
-$38.90 M |
-$45.50 M |
-$27.95 M |
-$20.65 M |
-$4.46 M |
-$1.91 M |
| Net Income Ratio |
-13.07 |
-3.06 |
-3.24 |
0 |
0 |
0 |
0 |
0 |
| EPS |
-1.48 |
-0.81 |
-1.44 |
-1.82 |
-1.12 |
-1.41 |
-0.22 |
-0.0959 |
| EPS Diluted |
-1.48 |
-0.81 |
-1.44 |
-1.82 |
-1.12 |
-1.41 |
-0.22 |
-0.0959 |
| Weighted Average Shares
Out |
$45.34 M
|
$34.16 M
|
$27.04 M
|
$25.00 M
|
$24.90 M
|
$14.66 M
|
$19.95 M
|
$19.95 M
|
| Weighted Average Shares
Out Diluted |
$45.34 M
|
$34.16 M
|
$27.04 M
|
$25.00 M
|
$24.90 M
|
$14.66 M
|
$19.95 M
|
$19.95 M
|
| Link |
|
|
|
|
|
|
|
|
